Literature DB >> 34059730

Neutrophil-to-lymphocyte ratio is associated with increased cerebral blood flow velocity in acute bacterial meningitis.

Lena Hueske1, Tobias Bobinger2, Antje Giede-Jeppe3, Selim Atay2, Julia Koehn2, Anne Mrochen2, Hannes Luecking4, Philip Hoelter4, Bastian Volbers2, Hagen B Huttner5.   

Abstract

In community-acquired bacterial meningitis (CABM) intracranial vascular alterations are devastating complications which are triggered by neuroinflammation and result in worse clinical outcome. The Neutrophil-to-Lymphocyte ratio (NLR) represents a reliable parameter of the inflammatory response. In this study we analyzed the association between NLR and elevated cerebral blood flow velocity (CBFv) in CABM-patients. This study included all (CABM)-patients admitted to a German tertiary center between 2006 and 2016. Patients' demographics, in-hospital measures, neuroradiological data and clinical outcome were retrieved from institutional databases. CBFv was assessed by transcranial doppler (TCD). Patients', radiological and laboratory characteristics were compared between patients with/without elevated CBFv. Multivariate-analysis investigated parameters independently associated with elevated CBFv. Receiver operating characteristic(ROC-)curve analysis was undertaken to identify the best cut-off for NLR to discriminate between increased CBFv. 108 patients with CABM were identified. 27.8% (30/108) showed elevated CBFv. Patients with elevated CBFv and normal CBFv, respectively had a worse clinical status on admission (Glasgow Coma Scale: 12 [9-14] vs. 14 [11-15]; p = 0.005) and required more often intensive care (30/30 [100.0%] vs. 63/78 [80.8%]; p = 0.01).The causative pathogen was S. pneumoniae in 70%. Patients with elevated CBFv developed more often cerebrovascular complications with delayed cerebral ischemia (DCI) within hospital stay (p = 0.031). A significantly higher admission-NLR was observed in patients with elevated CBFv (median [IQR]: elevated CBFv:24.0 [20.4-30.2] vs. normal CBFv:13.5 [8.4-19.5]; p < 0.001). Multivariate analysis, revealed NLR to be significantly associated with increased CBFv (Odds ratio [95%CI] 1.042 [1.003-1.084]; p = 0.036). ROC-analysis identified a NLR of 20.9 as best cut-off value to discriminate between elevated CBFv (AUC = 0.713, p < 0.0001, Youden's Index = 0.441;elevated CBFv: NLR ≥ 20.9 19/30[63.5%] vs. normal CBFv: NLR > 20.9 15/78[19.2%]; p < 0.001). Intracranial vascular complications are common among CABM-patients and are a risk factor for unfavorable outcome at discharge. Elevated NLR is independently associated with high CBFv and may be useful in predicting patients' prognosis.

Entities:  

Year:  2021        PMID: 34059730     DOI: 10.1038/s41598-021-90816-0

Source DB:  PubMed          Journal:  Sci Rep        ISSN: 2045-2322            Impact factor:   4.379


  38 in total

1.  Cerebrovascular complications of bacterial meningitis in adults.

Authors:  H W Pfister; G D Borasio; U Dirnagl; M Bauer; K M Einhäupl
Journal:  Neurology       Date:  1992-08       Impact factor: 9.910

2.  Studies on the pathogenesis of meningitis. II. Development of meningitis during pneumococcal bacteremia.

Authors:  R G PETERSDORF; D R SWARNER; M GARCIA
Journal:  J Clin Invest       Date:  1962-02       Impact factor: 14.808

Review 3.  Pathogenesis and pathophysiology of pneumococcal meningitis.

Authors:  Barry B Mook-Kanamori; Madelijn Geldhoff; Tom van der Poll; Diederik van de Beek
Journal:  Clin Microbiol Rev       Date:  2011-07       Impact factor: 26.132

4.  Progress and challenges in bacterial meningitis.

Authors:  Diederik van de Beek
Journal:  Lancet       Date:  2012-11-10       Impact factor: 79.321

Review 5.  Neutrophils at work.

Authors:  William M Nauseef; Niels Borregaard
Journal:  Nat Immunol       Date:  2014-07       Impact factor: 25.606

Review 6.  Effect of vaccines on bacterial meningitis worldwide.

Authors:  Peter B McIntyre; Katherine L O'Brien; Brian Greenwood; Diederik van de Beek
Journal:  Lancet       Date:  2012-11-10       Impact factor: 79.321

7.  Inflammasome activation mediates inflammation and outcome in humans and mice with pneumococcal meningitis.

Authors:  Madelijn Geldhoff; Barry B Mook-Kanamori; Matthijs C Brouwer; Dirk Troost; Jaklien C Leemans; Richard A Flavell; Arie Van der Ende; Tom Van der Poll; Diederik Van de Beek
Journal:  BMC Infect Dis       Date:  2013-07-31       Impact factor: 3.090

8.  The Role of Microglia in Bacterial Meningitis: Inflammatory Response, Experimental Models and New Neuroprotective Therapeutic Strategies.

Authors:  Sigrun Thorsdottir; Birgitta Henriques-Normark; Federico Iovino
Journal:  Front Microbiol       Date:  2019-03-25       Impact factor: 5.640

9.  Neutrophil extracellular traps in the central nervous system hinder bacterial clearance during pneumococcal meningitis.

Authors:  Tirthankar Mohanty; Jane Fisher; Anahita Bakochi; Ariane Neumann; José Francisco Pereira Cardoso; Christofer A Q Karlsson; Chiara Pavan; Iben Lundgaard; Bo Nilson; Peter Reinstrup; Johan Bonnevier; David Cederberg; Johan Malmström; Peter Bentzer; Adam Linder
Journal:  Nat Commun       Date:  2019-04-10       Impact factor: 14.919

10.  Pneumococcal meningitis: clinical-pathological correlations (MeninGene-Path).

Authors:  Joo-Yeon Engelen-Lee; Matthijs C Brouwer; Eleonora Aronica; Diederik van de Beek
Journal:  Acta Neuropathol Commun       Date:  2016-03-22       Impact factor: 7.801

View more
  2 in total

1.  Neutrophil lymphocyte ratio as predictor of mortality in pediatric patients with bacterial meningitis: A retrospective cohort study.

Authors:  Hardiman Widjaja; Desy Rusmawatiningtyas; Firdian Makrufardi; Eggi Arguni
Journal:  Ann Med Surg (Lond)       Date:  2021-12-21

2.  Amantadine treatment is associated with improved consciousness in patients with non-traumatic brain injury.

Authors:  Lena Rühl; Joji B Kuramatsu; Jochen A Sembill; Bernd Kallmünzer; Dominik Madzar; Stefan T Gerner; Antje Giede-Jeppe; Stefanie Balk; Tamara Mueller; Jakob Jäger; Stefan Schwab; Hagen B Huttner; Maximilian I Sprügel
Journal:  J Neurol Neurosurg Psychiatry       Date:  2022-01-27       Impact factor: 13.654

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.